Vesair Balloon Confirmatory Trial (VECTOR) (VECTOR)
Primary Purpose
Stress Urinary Incontinence
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vesair Balloon
Sponsored by
About this trial
This is an interventional treatment trial for Stress Urinary Incontinence
Eligibility Criteria
Inclusion Criteria:
- Previously treated with Vesair Balloon within the past 4 years
- Normal voiding function
- Has signed consent
- Willing to undergo cystoscopy
- Available for minimum of 12 months
Exclusion Criteria:
- Last Menstrual Period within past 4 years
- Systemic birth control medication (including implants) or systemic hormone replacement therapy (estrogen or progesterone) in the past 4 years.
- History of urosepsis, bladder infection, urinary tract infection or asymptomatic bacteriuria within the past 3 months.
- Urinary incontinence of neurogenic etiology.
- Prior pelvic surgery that may affect incontinence symptoms (including placement and/or removal of a suburethral sling) within the past 4 years.
- Noninvasive treatment for incontinence, such as nerve stimulation, Botox injections, biofeedback, formal pelvic floor muscle training, and/or vaginal laser therapy, within the past 3 months.
- Taken medications other than anticholinergics that may affect SUI symptoms (such as enobosarm, duloxetine or imipramine) in the past 3 months.
- Taking other pharmacologic agents that may have a significant effect on bladder function unless on the therapy for at least 3 months and intending to continue the same dosage of the medication throughout the trial.
- History of recurrent (>1) kidney stones, or one kidney stone within the past 5 years.
- History of an artificial urinary sphincter.
- Presence of gross hematuria and/or blood clots in the urine.
- History of interstitial or follicular cystitis or other painful bladder syndrome.
- Cystocele verified as Stage 3 or higher by PoP-Q Classification.
- Local genital skin infection.
- Urethral or bladder inflammation and/or edema, or other hypersensitivity to cystoscopy or other urethral manipulations.
- Evidence of involuntary detrusor contractions and/or discomfort during bladder filling up to 300cc.
- Undergoing or anticipating a course of pelvic radiation therapy or with severe pelvic fibrosis from previous radiation therapy.
- Non-ambulatory, bedridden or physically unable to complete test exercises.
- History of recent alcoholism or illicit drug abuse within the last year.
- Immunologically suppressed or immunocompromised.
- History of any neurological disease that could impact bladder function including Parkinson's disease, multiple sclerosis or post-stroke sequelae.
- Uncontrolled diabetes (persistent A1C levels >9 percent).
- History of any malignancy (except non-melanoma skin cancer), unless the cancer was not in the urinary tract, the cancer was stage II or less, the cancer was treated with curative intent, AND there have been no clinical signs or symptoms of the malignancy for at least 2 years.
- Morbid obesity, defined as BMI ≥40.0.
- History of any autoimmune or connective tissue disease or disorder that could impact bladder function
Sites / Locations
- WomanCare
- Regional Urology
- Chesapeake Urology
- Chesapeake Urology
- Premier Medical Group of the Hudson Valley
- Women and Infants dept of Urogynecology
- Urology of Virginia
- Washington Urology
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Treatment Arm
Arm Description
Single-arm of subjects who receive treatment with Vesair Balloon
Outcomes
Primary Outcome Measures
Provocative Pad Weight
in-office Pad weight test
Secondary Outcome Measures
Full Information
NCT ID
NCT03794206
First Posted
January 3, 2019
Last Updated
June 10, 2022
Sponsor
Solace Therapeutics, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03794206
Brief Title
Vesair Balloon Confirmatory Trial (VECTOR)
Acronym
VECTOR
Official Title
CD 1009 Rev A Page 1 of 44 23OCT2018 Vesair Balloon Confirmatory Trial (VECTOR) Use of the Next Generation Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Terminated
Why Stopped
Company closure
Study Start Date
February 11, 2019 (Actual)
Primary Completion Date
August 26, 2019 (Actual)
Study Completion Date
April 28, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Solace Therapeutics, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months. All subjects will be prospectively treated after the subject has provided informed consent and determination that all study entry criteria have been met.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress Urinary Incontinence
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment Arm
Arm Type
Experimental
Arm Description
Single-arm of subjects who receive treatment with Vesair Balloon
Intervention Type
Device
Intervention Name(s)
Vesair Balloon
Intervention Description
Treatment with Vesair Balloon for one year
Primary Outcome Measure Information:
Title
Provocative Pad Weight
Description
in-office Pad weight test
Time Frame
3 months
10. Eligibility
Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Previously treated with Vesair Balloon within the past 4 years
Normal voiding function
Has signed consent
Willing to undergo cystoscopy
Available for minimum of 12 months
Exclusion Criteria:
Last Menstrual Period within past 4 years
Systemic birth control medication (including implants) or systemic hormone replacement therapy (estrogen or progesterone) in the past 4 years.
History of urosepsis, bladder infection, urinary tract infection or asymptomatic bacteriuria within the past 3 months.
Urinary incontinence of neurogenic etiology.
Prior pelvic surgery that may affect incontinence symptoms (including placement and/or removal of a suburethral sling) within the past 4 years.
Noninvasive treatment for incontinence, such as nerve stimulation, Botox injections, biofeedback, formal pelvic floor muscle training, and/or vaginal laser therapy, within the past 3 months.
Taken medications other than anticholinergics that may affect SUI symptoms (such as enobosarm, duloxetine or imipramine) in the past 3 months.
Taking other pharmacologic agents that may have a significant effect on bladder function unless on the therapy for at least 3 months and intending to continue the same dosage of the medication throughout the trial.
History of recurrent (>1) kidney stones, or one kidney stone within the past 5 years.
History of an artificial urinary sphincter.
Presence of gross hematuria and/or blood clots in the urine.
History of interstitial or follicular cystitis or other painful bladder syndrome.
Cystocele verified as Stage 3 or higher by PoP-Q Classification.
Local genital skin infection.
Urethral or bladder inflammation and/or edema, or other hypersensitivity to cystoscopy or other urethral manipulations.
Evidence of involuntary detrusor contractions and/or discomfort during bladder filling up to 300cc.
Undergoing or anticipating a course of pelvic radiation therapy or with severe pelvic fibrosis from previous radiation therapy.
Non-ambulatory, bedridden or physically unable to complete test exercises.
History of recent alcoholism or illicit drug abuse within the last year.
Immunologically suppressed or immunocompromised.
History of any neurological disease that could impact bladder function including Parkinson's disease, multiple sclerosis or post-stroke sequelae.
Uncontrolled diabetes (persistent A1C levels >9 percent).
History of any malignancy (except non-melanoma skin cancer), unless the cancer was not in the urinary tract, the cancer was stage II or less, the cancer was treated with curative intent, AND there have been no clinical signs or symptoms of the malignancy for at least 2 years.
Morbid obesity, defined as BMI ≥40.0.
History of any autoimmune or connective tissue disease or disorder that could impact bladder function
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles Rardin, M.D.
Organizational Affiliation
Women and Infants Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
WomanCare
City
Arlington Heights
State/Province
Illinois
ZIP/Postal Code
60004
Country
United States
Facility Name
Regional Urology
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71106
Country
United States
Facility Name
Chesapeake Urology
City
Hanover
State/Province
Maryland
ZIP/Postal Code
21076
Country
United States
Facility Name
Chesapeake Urology
City
Owings Mills
State/Province
Maryland
ZIP/Postal Code
21117
Country
United States
Facility Name
Premier Medical Group of the Hudson Valley
City
Poughkeepsie
State/Province
New York
ZIP/Postal Code
12601
Country
United States
Facility Name
Women and Infants dept of Urogynecology
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Facility Name
Urology of Virginia
City
Virginia Beach
State/Province
Virginia
ZIP/Postal Code
23462
Country
United States
Facility Name
Washington Urology
City
Kirkland
State/Province
Washington
ZIP/Postal Code
98034
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29095516
Citation
McCammon K, Jacoby K, Kalota S, Snyder J, Cline K, Robertson K, Rardin C, Kahan R, Green L, Zuckerman J, Rovner E. Three-month primary efficacy data for the SUCCESS Trial; a phase III, multi-center, prospective, randomized, controlled study treating female stress urinary incontinence with the vesair intravesical balloon. Neurourol Urodyn. 2018 Jan;37(1):440-448. doi: 10.1002/nau.23324. Epub 2017 Nov 2.
Results Reference
background
Links:
URL
http://www.solacetx.com
Description
Company Website
Learn more about this trial
Vesair Balloon Confirmatory Trial (VECTOR)
We'll reach out to this number within 24 hrs